Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Long-Term Deferred Tax (2021 - 2023)

ADC Therapeutics has reported Long-Term Deferred Tax over the past 3 years, most recently at -$8.6 million for Q3 2023.

  • Quarterly results put Long-Term Deferred Tax at -$8.6 million for Q3 2023, down 125.72% from a year ago — trailing twelve months through Sep 2023 was -$8.6 million (down 125.72% YoY), and the annual figure for FY2022 was $37.1 million, up 142339.25%.
  • Long-Term Deferred Tax reached -$8.6 million in Q3 2023 per ADCT's latest filing, down from $34.8 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $37.1 million in Q4 2022 and bottomed at -$8.6 million in Q3 2023.
  • Median Long-Term Deferred Tax over the past 3 years was $31.8 million (2022), compared with a mean of $23.6 million.
  • The largest annual shift saw Long-Term Deferred Tax surged 142339.25% in 2022 before it tumbled 125.72% in 2023.
  • Over 3 years, Long-Term Deferred Tax stood at $26049.0 in 2021, then soared by 142339.25% to $37.1 million in 2022, then crashed by 123.29% to -$8.6 million in 2023.
  • Business Quant data shows Long-Term Deferred Tax for ADCT at -$8.6 million in Q3 2023, $34.8 million in Q2 2023, and $27.6 million in Q1 2023.